nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—CYP2E1—Methimazole—Graves' disease	0.413	0.487	CbGbCtD
Methotrimeprazine—CYP1A2—Methimazole—Graves' disease	0.239	0.281	CbGbCtD
Methotrimeprazine—CYP2D6—Methimazole—Graves' disease	0.197	0.232	CbGbCtD
Methotrimeprazine—DRD5—eyelid—Graves' disease	0.0386	0.574	CbGeAlD
Methotrimeprazine—Liver injury—Propylthiouracil—Graves' disease	0.0149	0.219	CcSEcCtD
Methotrimeprazine—Drowsiness—Methimazole—Graves' disease	0.00824	0.121	CcSEcCtD
Methotrimeprazine—Jaundice—Methimazole—Graves' disease	0.00803	0.118	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Methimazole—Graves' disease	0.00769	0.113	CcSEcCtD
Methotrimeprazine—Drowsiness—Propylthiouracil—Graves' disease	0.007	0.103	CcSEcCtD
Methotrimeprazine—Jaundice—Propylthiouracil—Graves' disease	0.00683	0.101	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Propylthiouracil—Graves' disease	0.00654	0.0963	CcSEcCtD
Methotrimeprazine—Somnolence—Methimazole—Graves' disease	0.00467	0.0688	CcSEcCtD
Methotrimeprazine—Somnolence—Propylthiouracil—Graves' disease	0.00397	0.0585	CcSEcCtD
Methotrimeprazine—CHRM5—eye—Graves' disease	0.00386	0.0573	CbGeAlD
Methotrimeprazine—DRD2—eye—Graves' disease	0.00194	0.0288	CbGeAlD
Methotrimeprazine—CHRM3—adipose tissue—Graves' disease	0.0016	0.0237	CbGeAlD
Methotrimeprazine—HRH1—eye—Graves' disease	0.00153	0.0228	CbGeAlD
Methotrimeprazine—HRH1—connective tissue—Graves' disease	0.00148	0.0219	CbGeAlD
Methotrimeprazine—ADRA1A—adipose tissue—Graves' disease	0.00146	0.0217	CbGeAlD
Methotrimeprazine—ADRA2A—connective tissue—Graves' disease	0.00145	0.0215	CbGeAlD
Methotrimeprazine—DRD2—pituitary gland—Graves' disease	0.00144	0.0214	CbGeAlD
Methotrimeprazine—ADRA2C—pituitary gland—Graves' disease	0.0014	0.0208	CbGeAlD
Methotrimeprazine—ADRA2C—adipose tissue—Graves' disease	0.0014	0.0207	CbGeAlD
Methotrimeprazine—CHRM3—thyroid gland—Graves' disease	0.00138	0.0205	CbGeAlD
Methotrimeprazine—HTR2A—eye—Graves' disease	0.00128	0.019	CbGeAlD
Methotrimeprazine—HTR2A—connective tissue—Graves' disease	0.00123	0.0183	CbGeAlD
Methotrimeprazine—HRH1—adipose tissue—Graves' disease	0.00113	0.0168	CbGeAlD
Methotrimeprazine—ADRA2A—pituitary gland—Graves' disease	0.00112	0.0166	CbGeAlD
Methotrimeprazine—ADRA2A—adipose tissue—Graves' disease	0.00111	0.0165	CbGeAlD
Methotrimeprazine—CYP1A2—thyroid gland—Graves' disease	0.00105	0.0156	CbGeAlD
Methotrimeprazine—ADRA2A—thyroid gland—Graves' disease	0.000964	0.0143	CbGeAlD
Methotrimeprazine—HTR2A—pituitary gland—Graves' disease	0.000951	0.0141	CbGeAlD
Methotrimeprazine—CYP2E1—thyroid gland—Graves' disease	0.000943	0.014	CbGeAlD
Methotrimeprazine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.07e-05	0.00333	CbGpPWpGaD
Methotrimeprazine—ADRA2C—G alpha (i) signalling events—CXCL10—Graves' disease	5.06e-05	0.00332	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	5.06e-05	0.00332	CbGpPWpGaD
Methotrimeprazine—HTR2C—GPCR ligand binding—TSHR—Graves' disease	4.88e-05	0.0032	CbGpPWpGaD
Methotrimeprazine—DRD5—GPCR downstream signaling—TSHR—Graves' disease	4.85e-05	0.00318	CbGpPWpGaD
Methotrimeprazine—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.84e-05	0.00317	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.77e-05	0.00313	CbGpPWpGaD
Methotrimeprazine—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.77e-05	0.00313	CbGpPWpGaD
Methotrimeprazine—ADRA2C—GPCR ligand binding—TSHR—Graves' disease	4.74e-05	0.00311	CbGpPWpGaD
Methotrimeprazine—ADRA1B—GPCR ligand binding—TSHR—Graves' disease	4.67e-05	0.00306	CbGpPWpGaD
Methotrimeprazine—DRD2—G alpha (i) signalling events—CXCL10—Graves' disease	4.59e-05	0.00301	CbGpPWpGaD
Methotrimeprazine—CHRM2—G alpha (i) signalling events—CXCL10—Graves' disease	4.44e-05	0.00291	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling by GPCR—TSHR—Graves' disease	4.4e-05	0.00289	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	4.35e-05	0.00285	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.31e-05	0.00283	CbGpPWpGaD
Methotrimeprazine—DRD2—GPCR ligand binding—TSHR—Graves' disease	4.3e-05	0.00282	CbGpPWpGaD
Methotrimeprazine—HTR2A—GPCR ligand binding—TSHR—Graves' disease	4.23e-05	0.00278	CbGpPWpGaD
Methotrimeprazine—HRH1—GPCR ligand binding—TSHR—Graves' disease	4.22e-05	0.00277	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	4.22e-05	0.00277	CbGpPWpGaD
Methotrimeprazine—CHRM1—GPCR ligand binding—TSHR—Graves' disease	4.21e-05	0.00276	CbGpPWpGaD
Methotrimeprazine—CHRM3—GPCR ligand binding—TSHR—Graves' disease	4.2e-05	0.00275	CbGpPWpGaD
Methotrimeprazine—CHRM2—GPCR ligand binding—TSHR—Graves' disease	4.16e-05	0.00273	CbGpPWpGaD
Methotrimeprazine—ADRA1A—GPCR ligand binding—TSHR—Graves' disease	4.15e-05	0.00272	CbGpPWpGaD
Methotrimeprazine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.14e-05	0.00272	CbGpPWpGaD
Methotrimeprazine—ADRA2A—G alpha (i) signalling events—CXCL10—Graves' disease	4.11e-05	0.0027	CbGpPWpGaD
Methotrimeprazine—DRD4—GPCR ligand binding—CXCL10—Graves' disease	4.09e-05	0.00268	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	4.06e-05	0.00267	CbGpPWpGaD
Methotrimeprazine—CHRM4—GPCR ligand binding—CXCL10—Graves' disease	4.04e-05	0.00265	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.02e-05	0.00264	CbGpPWpGaD
Methotrimeprazine—DRD2—Circadian rythm related genes—FAS—Graves' disease	4e-05	0.00263	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	3.96e-05	0.0026	CbGpPWpGaD
Methotrimeprazine—CHRM1—Circadian rythm related genes—FAS—Graves' disease	3.91e-05	0.00257	CbGpPWpGaD
Methotrimeprazine—CHRM5—GPCR ligand binding—CXCL10—Graves' disease	3.86e-05	0.00254	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR ligand binding—TSHR—Graves' disease	3.85e-05	0.00253	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	3.76e-05	0.00247	CbGpPWpGaD
Methotrimeprazine—DRD1—GPCR ligand binding—CXCL10—Graves' disease	3.68e-05	0.00242	CbGpPWpGaD
Methotrimeprazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	3.65e-05	0.0024	CbGpPWpGaD
Methotrimeprazine—ADRA1D—GPCR ligand binding—CXCL10—Graves' disease	3.63e-05	0.00238	CbGpPWpGaD
Methotrimeprazine—DRD3—GPCR ligand binding—CXCL10—Graves' disease	3.63e-05	0.00238	CbGpPWpGaD
Methotrimeprazine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	3.59e-05	0.00236	CbGpPWpGaD
Methotrimeprazine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	3.58e-05	0.00235	CbGpPWpGaD
Methotrimeprazine—DRD4—GPCR downstream signaling—TSHR—Graves' disease	3.58e-05	0.00235	CbGpPWpGaD
Methotrimeprazine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	3.57e-05	0.00235	CbGpPWpGaD
Methotrimeprazine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	3.56e-05	0.00234	CbGpPWpGaD
Methotrimeprazine—CHRM4—GPCR downstream signaling—TSHR—Graves' disease	3.53e-05	0.00232	CbGpPWpGaD
Methotrimeprazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	3.53e-05	0.00232	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	3.52e-05	0.00231	CbGpPWpGaD
Methotrimeprazine—CHRM5—GPCR downstream signaling—TSHR—Graves' disease	3.38e-05	0.00222	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	3.3e-05	0.00217	CbGpPWpGaD
Methotrimeprazine—ADRA2B—GPCR ligand binding—CXCL10—Graves' disease	3.28e-05	0.00215	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	3.27e-05	0.00215	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—TSHR—Graves' disease	3.25e-05	0.00213	CbGpPWpGaD
Methotrimeprazine—DRD1—GPCR downstream signaling—TSHR—Graves' disease	3.22e-05	0.00211	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—TSHR—Graves' disease	3.2e-05	0.0021	CbGpPWpGaD
Methotrimeprazine—ADRA1D—GPCR downstream signaling—TSHR—Graves' disease	3.18e-05	0.00209	CbGpPWpGaD
Methotrimeprazine—DRD3—GPCR downstream signaling—TSHR—Graves' disease	3.18e-05	0.00209	CbGpPWpGaD
Methotrimeprazine—HTR2C—GPCR ligand binding—CXCL10—Graves' disease	3.15e-05	0.00207	CbGpPWpGaD
Methotrimeprazine—DRD5—GPCR downstream signaling—CXCL10—Graves' disease	3.13e-05	0.00206	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—TSHR—Graves' disease	3.07e-05	0.00201	CbGpPWpGaD
Methotrimeprazine—ADRA2C—GPCR ligand binding—CXCL10—Graves' disease	3.06e-05	0.00201	CbGpPWpGaD
Methotrimeprazine—ADRA1B—GPCR ligand binding—CXCL10—Graves' disease	3.02e-05	0.00198	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—TSHR—Graves' disease	2.92e-05	0.00192	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—TSHR—Graves' disease	2.89e-05	0.00189	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—TSHR—Graves' disease	2.89e-05	0.00189	CbGpPWpGaD
Methotrimeprazine—ADRA2B—GPCR downstream signaling—TSHR—Graves' disease	2.87e-05	0.00188	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling by GPCR—CXCL10—Graves' disease	2.84e-05	0.00187	CbGpPWpGaD
Methotrimeprazine—HTR2A—SIDS Susceptibility Pathways—IL1B—Graves' disease	2.82e-05	0.00185	CbGpPWpGaD
Methotrimeprazine—DRD2—GPCR ligand binding—CXCL10—Graves' disease	2.78e-05	0.00182	CbGpPWpGaD
Methotrimeprazine—CHRM2—SIDS Susceptibility Pathways—IL1B—Graves' disease	2.77e-05	0.00182	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	2.76e-05	0.00181	CbGpPWpGaD
Methotrimeprazine—HTR2C—GPCR downstream signaling—TSHR—Graves' disease	2.75e-05	0.00181	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—GC—Graves' disease	2.74e-05	0.0018	CbGpPWpGaD
Methotrimeprazine—HTR2A—GPCR ligand binding—CXCL10—Graves' disease	2.74e-05	0.0018	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	2.73e-05	0.00179	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	2.73e-05	0.00179	CbGpPWpGaD
Methotrimeprazine—HRH1—GPCR ligand binding—CXCL10—Graves' disease	2.73e-05	0.00179	CbGpPWpGaD
Methotrimeprazine—CHRM1—GPCR ligand binding—CXCL10—Graves' disease	2.72e-05	0.00179	CbGpPWpGaD
Methotrimeprazine—CHRM3—GPCR ligand binding—CXCL10—Graves' disease	2.71e-05	0.00178	CbGpPWpGaD
Methotrimeprazine—CHRM2—GPCR ligand binding—CXCL10—Graves' disease	2.69e-05	0.00176	CbGpPWpGaD
Methotrimeprazine—ADRA2C—GPCR downstream signaling—TSHR—Graves' disease	2.68e-05	0.00176	CbGpPWpGaD
Methotrimeprazine—ADRA1A—GPCR ligand binding—CXCL10—Graves' disease	2.68e-05	0.00176	CbGpPWpGaD
Methotrimeprazine—ADRA1B—GPCR downstream signaling—TSHR—Graves' disease	2.64e-05	0.00173	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—TSHR—Graves' disease	2.61e-05	0.00171	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—TSHR—Graves' disease	2.6e-05	0.00171	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—TSHR—Graves' disease	2.5e-05	0.00164	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR ligand binding—CXCL10—Graves' disease	2.49e-05	0.00163	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—TSHR—Graves' disease	2.43e-05	0.0016	CbGpPWpGaD
Methotrimeprazine—DRD2—GPCR downstream signaling—TSHR—Graves' disease	2.43e-05	0.0016	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—GC—Graves' disease	2.42e-05	0.00159	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—TSHR—Graves' disease	2.39e-05	0.00157	CbGpPWpGaD
Methotrimeprazine—DRD5—GPCR downstream signaling—IL2RA—Graves' disease	2.39e-05	0.00157	CbGpPWpGaD
Methotrimeprazine—HTR2A—GPCR downstream signaling—TSHR—Graves' disease	2.39e-05	0.00157	CbGpPWpGaD
Methotrimeprazine—HRH1—GPCR downstream signaling—TSHR—Graves' disease	2.39e-05	0.00157	CbGpPWpGaD
Methotrimeprazine—CHRM1—GPCR downstream signaling—TSHR—Graves' disease	2.38e-05	0.00156	CbGpPWpGaD
Methotrimeprazine—CHRM3—GPCR downstream signaling—TSHR—Graves' disease	2.37e-05	0.00156	CbGpPWpGaD
Methotrimeprazine—CHRM2—GPCR downstream signaling—TSHR—Graves' disease	2.35e-05	0.00154	CbGpPWpGaD
Methotrimeprazine—ADRA1A—GPCR downstream signaling—TSHR—Graves' disease	2.34e-05	0.00154	CbGpPWpGaD
Methotrimeprazine—DRD4—GPCR downstream signaling—CXCL10—Graves' disease	2.31e-05	0.00152	CbGpPWpGaD
Methotrimeprazine—CHRM4—GPCR downstream signaling—CXCL10—Graves' disease	2.28e-05	0.0015	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Hemostasis—IL2RA—Graves' disease	2.24e-05	0.00147	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—GC—Graves' disease	2.22e-05	0.00146	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—TSHR—Graves' disease	2.21e-05	0.00145	CbGpPWpGaD
Methotrimeprazine—CHRM5—GPCR downstream signaling—CXCL10—Graves' disease	2.18e-05	0.00143	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—TSHR—Graves' disease	2.18e-05	0.00143	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling by GPCR—IL2RA—Graves' disease	2.17e-05	0.00143	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—TSHR—Graves' disease	2.17e-05	0.00143	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—TSHR—Graves' disease	2.17e-05	0.00142	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—TSHR—Graves' disease	2.16e-05	0.00142	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—TSHR—Graves' disease	2.15e-05	0.00141	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—TSHR—Graves' disease	2.13e-05	0.0014	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—TSHR—Graves' disease	2.13e-05	0.0014	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—CXCL10—Graves' disease	2.1e-05	0.00138	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Hemostasis—IL2RA—Graves' disease	2.09e-05	0.00137	CbGpPWpGaD
Methotrimeprazine—DRD1—GPCR downstream signaling—CXCL10—Graves' disease	2.08e-05	0.00137	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—B3GNT2—Graves' disease	2.07e-05	0.00136	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—CXCL10—Graves' disease	2.07e-05	0.00136	CbGpPWpGaD
Methotrimeprazine—ADRA1D—GPCR downstream signaling—CXCL10—Graves' disease	2.05e-05	0.00135	CbGpPWpGaD
Methotrimeprazine—DRD3—GPCR downstream signaling—CXCL10—Graves' disease	2.05e-05	0.00135	CbGpPWpGaD
Methotrimeprazine—HTR2A—SIDS Susceptibility Pathways—TNF—Graves' disease	2.05e-05	0.00134	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—GC—Graves' disease	2.04e-05	0.00134	CbGpPWpGaD
Methotrimeprazine—CHRM2—SIDS Susceptibility Pathways—TNF—Graves' disease	2.01e-05	0.00132	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—CXCL10—Graves' disease	1.98e-05	0.0013	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—TSHR—Graves' disease	1.98e-05	0.0013	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—TSHR—Graves' disease	1.92e-05	0.00126	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—TSHR—Graves' disease	1.89e-05	0.00124	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—CXCL10—Graves' disease	1.89e-05	0.00124	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—CXCL10—Graves' disease	1.86e-05	0.00122	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—CXCL10—Graves' disease	1.86e-05	0.00122	CbGpPWpGaD
Methotrimeprazine—ADRA2B—GPCR downstream signaling—CXCL10—Graves' disease	1.85e-05	0.00122	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—B3GNT2—Graves' disease	1.84e-05	0.00121	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—TSHR—Graves' disease	1.81e-05	0.00119	CbGpPWpGaD
Methotrimeprazine—HTR2C—GPCR downstream signaling—CXCL10—Graves' disease	1.78e-05	0.00117	CbGpPWpGaD
Methotrimeprazine—DRD4—GPCR downstream signaling—IL2RA—Graves' disease	1.77e-05	0.00116	CbGpPWpGaD
Methotrimeprazine—CHRM4—GPCR downstream signaling—IL2RA—Graves' disease	1.74e-05	0.00114	CbGpPWpGaD
Methotrimeprazine—ADRA2C—GPCR downstream signaling—CXCL10—Graves' disease	1.73e-05	0.00114	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—TSHR—Graves' disease	1.73e-05	0.00113	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—TSHR—Graves' disease	1.7e-05	0.00112	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—TSHR—Graves' disease	1.7e-05	0.00112	CbGpPWpGaD
Methotrimeprazine—ADRA1B—GPCR downstream signaling—CXCL10—Graves' disease	1.7e-05	0.00112	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Hemostasis—IL2RA—Graves' disease	1.7e-05	0.00112	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—B3GNT2—Graves' disease	1.69e-05	0.00111	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—CXCL10—Graves' disease	1.68e-05	0.0011	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—CXCL10—Graves' disease	1.68e-05	0.0011	CbGpPWpGaD
Methotrimeprazine—CHRM5—GPCR downstream signaling—IL2RA—Graves' disease	1.67e-05	0.0011	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—CXCL10—Graves' disease	1.62e-05	0.00106	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—IL2RA—Graves' disease	1.6e-05	0.00105	CbGpPWpGaD
Methotrimeprazine—DRD1—GPCR downstream signaling—IL2RA—Graves' disease	1.59e-05	0.00104	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—IL2RA—Graves' disease	1.58e-05	0.00104	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—CXCL10—Graves' disease	1.57e-05	0.00103	CbGpPWpGaD
Methotrimeprazine—DRD2—GPCR downstream signaling—CXCL10—Graves' disease	1.57e-05	0.00103	CbGpPWpGaD
Methotrimeprazine—ADRA1D—GPCR downstream signaling—IL2RA—Graves' disease	1.57e-05	0.00103	CbGpPWpGaD
Methotrimeprazine—DRD3—GPCR downstream signaling—IL2RA—Graves' disease	1.57e-05	0.00103	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—CXCL10—Graves' disease	1.55e-05	0.00102	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—B3GNT2—Graves' disease	1.55e-05	0.00102	CbGpPWpGaD
Methotrimeprazine—HTR2A—GPCR downstream signaling—CXCL10—Graves' disease	1.55e-05	0.00101	CbGpPWpGaD
Methotrimeprazine—HRH1—GPCR downstream signaling—CXCL10—Graves' disease	1.54e-05	0.00101	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TSHR—Graves' disease	1.54e-05	0.00101	CbGpPWpGaD
Methotrimeprazine—CHRM1—GPCR downstream signaling—CXCL10—Graves' disease	1.54e-05	0.00101	CbGpPWpGaD
Methotrimeprazine—CHRM3—GPCR downstream signaling—CXCL10—Graves' disease	1.53e-05	0.00101	CbGpPWpGaD
Methotrimeprazine—CHRM2—GPCR downstream signaling—CXCL10—Graves' disease	1.52e-05	0.000996	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—IL2RA—Graves' disease	1.52e-05	0.000995	CbGpPWpGaD
Methotrimeprazine—ADRA1A—GPCR downstream signaling—CXCL10—Graves' disease	1.51e-05	0.000994	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TSHR—Graves' disease	1.48e-05	0.00097	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—GC—Graves' disease	1.45e-05	0.000951	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—IL2RA—Graves' disease	1.44e-05	0.000948	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TSHR—Graves' disease	1.44e-05	0.000943	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—CXCL10—Graves' disease	1.43e-05	0.000936	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—IL2RA—Graves' disease	1.43e-05	0.000935	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—IL2RA—Graves' disease	1.43e-05	0.000935	CbGpPWpGaD
Methotrimeprazine—ADRA2B—GPCR downstream signaling—IL2RA—Graves' disease	1.42e-05	0.00093	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TSHR—Graves' disease	1.41e-05	0.000929	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—CXCL10—Graves' disease	1.41e-05	0.000923	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—CXCL10—Graves' disease	1.4e-05	0.000921	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—CXCL10—Graves' disease	1.4e-05	0.000919	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—CXCL10—Graves' disease	1.4e-05	0.000916	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—CXCL10—Graves' disease	1.39e-05	0.000914	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—CXCL10—Graves' disease	1.38e-05	0.000905	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—CXCL10—Graves' disease	1.37e-05	0.000902	CbGpPWpGaD
Methotrimeprazine—HTR2C—GPCR downstream signaling—IL2RA—Graves' disease	1.36e-05	0.000893	CbGpPWpGaD
Methotrimeprazine—ADRA2C—GPCR downstream signaling—IL2RA—Graves' disease	1.32e-05	0.000869	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TSHR—Graves' disease	1.3e-05	0.000856	CbGpPWpGaD
Methotrimeprazine—ADRA1B—GPCR downstream signaling—IL2RA—Graves' disease	1.3e-05	0.000855	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—IL2RA—Graves' disease	1.29e-05	0.000844	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—IL2RA—Graves' disease	1.28e-05	0.000843	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TSHR—Graves' disease	1.28e-05	0.000842	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TSHR—Graves' disease	1.28e-05	0.000841	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—CXCL10—Graves' disease	1.28e-05	0.000838	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TSHR—Graves' disease	1.28e-05	0.000838	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TSHR—Graves' disease	1.27e-05	0.000835	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TSHR—Graves' disease	1.26e-05	0.000827	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TSHR—Graves' disease	1.26e-05	0.000825	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—CXCL10—Graves' disease	1.24e-05	0.000814	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—IL2RA—Graves' disease	1.24e-05	0.000811	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—GC—Graves' disease	1.23e-05	0.000806	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—CXCL10—Graves' disease	1.22e-05	0.000803	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—IL2RA—Graves' disease	1.2e-05	0.000789	CbGpPWpGaD
Methotrimeprazine—DRD2—GPCR downstream signaling—IL2RA—Graves' disease	1.2e-05	0.000788	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—IL2RA—Graves' disease	1.18e-05	0.000776	CbGpPWpGaD
Methotrimeprazine—HTR2A—GPCR downstream signaling—IL2RA—Graves' disease	1.18e-05	0.000776	CbGpPWpGaD
Methotrimeprazine—HRH1—GPCR downstream signaling—IL2RA—Graves' disease	1.18e-05	0.000774	CbGpPWpGaD
Methotrimeprazine—CHRM1—GPCR downstream signaling—IL2RA—Graves' disease	1.18e-05	0.000771	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—CXCL10—Graves' disease	1.17e-05	0.000769	CbGpPWpGaD
Methotrimeprazine—CHRM3—GPCR downstream signaling—IL2RA—Graves' disease	1.17e-05	0.000769	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TSHR—Graves' disease	1.17e-05	0.000766	CbGpPWpGaD
Methotrimeprazine—CHRM2—GPCR downstream signaling—IL2RA—Graves' disease	1.16e-05	0.000761	CbGpPWpGaD
Methotrimeprazine—ADRA1A—GPCR downstream signaling—IL2RA—Graves' disease	1.16e-05	0.000759	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—CXCL10—Graves' disease	1.12e-05	0.000733	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—CXCL10—Graves' disease	1.1e-05	0.000723	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—CXCL10—Graves' disease	1.1e-05	0.000723	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—B3GNT2—Graves' disease	1.1e-05	0.000721	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—IL2RA—Graves' disease	1.09e-05	0.000716	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—IL2RA—Graves' disease	1.07e-05	0.000706	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—IL2RA—Graves' disease	1.07e-05	0.000704	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—IL2RA—Graves' disease	1.07e-05	0.000703	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—IL2RA—Graves' disease	1.07e-05	0.0007	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—IL2RA—Graves' disease	1.06e-05	0.000698	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—IL2RA—Graves' disease	1.05e-05	0.000691	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—IL2RA—Graves' disease	1.05e-05	0.00069	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CXCL10—Graves' disease	9.94e-06	0.000653	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—IL2RA—Graves' disease	9.76e-06	0.000641	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CXCL10—Graves' disease	9.55e-06	0.000627	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—IL2RA—Graves' disease	9.48e-06	0.000622	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—IL2RA—Graves' disease	9.35e-06	0.000614	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—B3GNT2—Graves' disease	9.3e-06	0.000611	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CXCL10—Graves' disease	9.29e-06	0.00061	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CXCL10—Graves' disease	9.14e-06	0.0006	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—IL2RA—Graves' disease	8.95e-06	0.000588	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—IL2RA—Graves' disease	8.53e-06	0.00056	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CXCL10—Graves' disease	8.43e-06	0.000553	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—IL2RA—Graves' disease	8.42e-06	0.000553	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—IL2RA—Graves' disease	8.42e-06	0.000553	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CXCL10—Graves' disease	8.29e-06	0.000544	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CXCL10—Graves' disease	8.28e-06	0.000543	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CXCL10—Graves' disease	8.25e-06	0.000541	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CXCL10—Graves' disease	8.22e-06	0.00054	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CXCL10—Graves' disease	8.14e-06	0.000534	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CXCL10—Graves' disease	8.12e-06	0.000533	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IL2RA—Graves' disease	7.6e-06	0.000499	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CXCL10—Graves' disease	7.54e-06	0.000495	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL2RA—Graves' disease	7.3e-06	0.000479	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL2RA—Graves' disease	7.1e-06	0.000466	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL2RA—Graves' disease	6.99e-06	0.000459	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL2RA—Graves' disease	6.44e-06	0.000423	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL2RA—Graves' disease	6.34e-06	0.000416	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL2RA—Graves' disease	6.32e-06	0.000415	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL2RA—Graves' disease	6.3e-06	0.000414	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL2RA—Graves' disease	6.28e-06	0.000412	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL2RA—Graves' disease	6.22e-06	0.000408	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL2RA—Graves' disease	6.21e-06	0.000407	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL2RA—Graves' disease	5.77e-06	0.000378	CbGpPWpGaD
